Ozempic, the celebrated medication known for managing diabetes and aiding weight loss, is set to launch in generic form soon in India, China, and Canada-offering a promising path to more affordable access as global demand skyrockets, reports The New York Times
Generic Ozempic is set to revolutionize access for billions worldwide, making this breakthrough diabetes and weight management medication more affordable than ever. Experts foresee a game-changing shift in how treatments are delivered and priced across the globe
China is targeting the globe’s most expensive drugs with a bold mission: to dramatically cut costs and make life-saving treatments accessible to more patients. This ambitious move is shaking up the global pharmaceutical scene, transforming pricing strategies and sparking fresh waves of innovation throughout the industry
China is boldly challenging the U.S.’ leadership in pharmaceutical manufacturing as the Trump administration shakes up research policies. This dramatic shift sparks worries about America’s future grip on drug-making supremacy
AstraZeneca is making a bold leap with a $15 billion investment in China through 2030, cementing its role as a leader in next-generation innovative medicine and expanding its presence in one of the world’s fastest-growing healthcare markets
Canada is set to emerge as a key contender in the global race to produce generic versions of Ozempic, the popular diabetes medication, as manufacturers prepare for accelerated approvals and exciting new market opportunities on the horizon
Samsung Bioepis has just reached a thrilling milestone by securing Japan’s regulatory approval for its Stelara biosimilar, opening the door to a powerful presence in Asia’s rapidly growing biologics market, The Korea Herald reports
The US has announced an exciting plan to cut biosimilar development costs by 50% for India’s Biocon, a top executive told Reuters. This ambitious move aims to boost access to affordable biologics and strengthen the growing pharmaceutical alliance between the US and India
Novo Nordisk (NVO:NYSE) has boldly cut the price of its weight-loss drug Wegovy in India, making it more affordable and set to take the lead in the fast-growing obesity treatment market
Australia’s Neuren Pharma shares plunged to their lowest level in more than two months after the company dramatically cut its royalty forecast, sparking investor concerns over potential profit declines. Market watchers remain on edge as the stock faces renewed selling pressure
RAMM Pharma Corp. has just shared a crucial update regarding the Canada Post strike, warning shareholders that there may be delays in receiving the company’s meeting materials. Stay alert and watch your inbox for the latest news!
MercadoLibre (MELI) shares dipped after the e-commerce giant made a daring move into Brazil’s pharmacy market. With competition intensifying, investors are closely watching to see what this bold step means for the company’s future. Could this be your next big chance to buy in?
Eli Lilly is gearing up to invest over $1 billion in India, dramatically boosting its manufacturing power to keep pace with the skyrocketing demand across the region, Reuters reports
Advocacy groups are urging regulators to launch a bold anticompetition probe into Big Pharma’s moves after Brexit, accusing the industry of manipulating the market and driving prices sky-high. This call highlights growing concerns over pharmaceutical practices in the evolving post-Brexit landscape
Merck is scaling back its major operations in the UK, raising alarms about Britain’s capacity to retain its thriving life sciences sector amid rising costs and tangled regulations. Industry experts warn that this decision could put the future of the nation’s biotech industry at serious risk
The EU has launched a thorough investigation into France’s Sanofi, zeroing in on its vaccine business amid growing worries about anti-competitive practices. This bold step underscores the heightened scrutiny pharmaceutical giants are under in the post-pandemic world
UK Trade Secretary has launched a fierce critique of the pharmaceutical industry amid heated price negotiations, highlighting soaring drug costs and demanding fairer pricing as critical trade talks loom
Former President Donald Trump has introduced bold new drug tariffs aimed at dramatically cutting U.S. pharmaceutical prices. Experts weigh in on what these changes could mean for the cost of your medications at the pharmacy. Stay updated with USA Today
The US is preparing to impose new tariffs on pharmaceutical imports, kitchen cabinets, furniture, and heavy trucks, intensifying trade tensions. Stay tuned for live updates on how this bold move will impact industries and ignite reactions across the board
Indian pharma stocks plunged sharply following President Trump’s announcement of new drug tariffs. However, analysts urge investors not to panic, highlighting that this sell-off is largely sentiment-driven and the sector’s strong fundamentals remain intact despite the market turbulence
